Bayer Outlines Asundexian Phase III Plan, Hoping To Prove Safety Benefit Over Eliquis

Bayer AG is initiating a large Phase III clinical trial program enrolling more than 30,000 patients to investigate its next-generation Factor XIa inhibitor asundexian, with the goal of developing an effective oral anticoagulant with an improved safety profile over the current standard of care, its own Xarelto (rivaroxaban) and Bristol Myers Squibb Company/Pfizer Inc.'s Eliquis (apixaban).

Bayer outlined plans for the late-stage development of asundexian – one of the company's high-profile pipeline assets – during the European Society of Cardiology Congress in Barcelona on 28 August